At a glance
- Originator Nonindustrial source
- Class Antineoplastics
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 17 Oct 2000 P 1013 is available for licensing
- 17 Oct 2000 Preclinical development for Cancer in Norway (Unknown route)
- 05 Aug 1998 Profile reviewed